Polymorphisms in ERCC2 and overall survival (OS) in early stage non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Suk, R
Park, S
Liu, G
Cogan-Drew, T
Zhou, W
Su, L
Lynch, T
Wain, J
Christiani, D
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：842S / 842S
页数：1
相关论文
共 50 条
  • [31] Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum
    Liao, Wei-Yu
    Ho, Chao-Chi
    Tsai, Tzu-Hsiu
    Chen, Kuan-Yu
    Shih, Jin-Yuan
    Yu, Chong-Jen
    LUNG CANCER, 2018, 118 : 90 - 96
  • [32] Early Changes in Body Composition in Metastatic Non-Small Cell Lung Cancer (NSCLC) Are Predictive for Poor Overall Survival
    Degens, J.
    Sanders, K.
    De Jong, E.
    Schols, A.
    Dingemans, A.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2086 - S2087
  • [33] Correlation of radiomic features with PD-L1 expression in early stage non-small cell lung cancer (ES-NSCLC) to predict recurrence and overall survival (OS).
    Patil, Pradnya Dinkar
    Bera, Kaustav
    Vaidya, Pranjal
    Prasanna, Prateek
    Khunger, Monica
    Khunger, Arjun
    Velcheti, Vamsidhar
    Madabhushi, Anant
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] Overall survival outcome of an early stage non-small cell lung cancer in stereotactic radiosurgery: Systematic review
    Siregar, Axel Sebastian
    Law, Natasha Karlina
    Kusuma, Indra
    Wijovi, Felix
    Kurniawan, Andree
    Giselvania, Angela
    ANNALS OF ONCOLOGY, 2021, 32 : S334 - S334
  • [35] Overall Survival (OS) of Pathological T1N0 Non-Small Cell Lung Cancer (NSCLC) After Resection
    Bourdages-Pageau, E.
    Vieira, A.
    Labbe, C.
    Figueroa, P. Ugalde
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2410 - S2411
  • [36] The Plasma Concentration of Epidermal Growth Factor Receptor (EGFR) and Overall Survival (OS) in Non-Small Cell Lung Cancer (NSCLC) Patients
    Ye, P.
    Zhao, J.
    Maihle, N.
    Wang, S. L.
    Jin, J. Y.
    Kong, F. M. P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E445 - E445
  • [37] Time trends in overall survival (OS) gain in advanced non-small-cell lung cancer (NSCLC).
    Saad, Everardo D.
    Buyse, Marc E.
    Jassem, Jacek
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Waiting times in early-stage non-small cell lung cancer (NSCLC)
    Saint-Jacques, Nathalie
    Rayson, Daniel
    Al-Fayea, Turki
    Virik, Kiran
    Morzycki, Wojciech
    Younis, Tallal
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (08) : 865 - 870
  • [39] Proton therapy for early-stage non-small cell lung cancer (NSCLC)
    Gomez, Daniel R.
    Li, Heng
    Chang, Joe Y.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (02) : 199 - 204
  • [40] Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer
    Heist, Rebecca Suk
    Marshall, Ariela L.
    Liu, Geoffrey
    Zhou, Wei
    Su, Li
    Neuberg, Donna
    Lynch, Thomas J.
    Wain, John
    Christiani, David C.
    CLINICAL CANCER RESEARCH, 2006, 12 (18) : 5448 - 5453
12345